---
id: 063
title: Voriconazole Side Effects and Therapeutic Drug Monitoring
category: antimicrobials
subcategory: azoles
tags: [voriconazole, visual-disturbances, hepatotoxicity, CYP2C19, TDM]
difficulty: hard
---

## Question

What are the major side effects of voriconazole, and why is therapeutic drug monitoring (TDM) essential? Use the **"VISUAL-LIVER-TDM"** mnemonic.

## Answer

### **"VISUAL-LIVER-TDM" Mnemonic:**

**VISUAL:**
- **V**ision changes (18% incidence)
- **I**ncreased light sensitivity (photophobia)
- **S**uperimposed colors, halos
- **U**sually reversible
- **A**t trough >5 µg/mL
- **L**asts 30 minutes (transient)

**LIVER:**
- **L**iver enzyme elevation (11-19%)
- **I**njury can be severe (hepatitis, failure)
- **V**ariable patterns (cholestatic/hepatocellular)
- **E**levated ALT/AST common
- **R**equires monitoring (weekly initially)

**TDM:**
- **T**arget trough: 1-5 µg/mL
- **D**ose adjust based on CYP2C19 genotype
- **M**onitor to prevent toxicity and ensure efficacy

### **Major Side Effects:**

#### **1. Visual Disturbances (Most Common - 18%):**

**Clinical Presentation:**
- **Photophobia** (light sensitivity)
- **Altered color perception**
- **Blurred vision, halos**
- **Enhanced visual brightness**
- **Wavy lines, flashing lights**

**Timing:** Occurs within 30 minutes of dose, lasts 30-60 minutes

**Risk Factors:**
- **Trough >5 µg/mL** (dose-related)
- High doses
- CYP2C19 poor metabolizers

**Management:**
- Usually **benign and reversible**
- Counsel patients before starting
- Reduce dose if bothersome or trough >5 µg/mL
- **Do NOT discontinue** unless severe

#### **2. Hepatotoxicity (11-19%):**

**Incidence:**
- Transient ALT elevation: 11-19%
- Severe hepatotoxicity requiring discontinuation: ~1%
- **69% in patients with baseline liver dysfunction** vs 16% in normal liver

**Presentation:**
- Elevated AST/ALT (>3× ULN)
- Variable patterns: cholestatic, hepatocellular, mixed
- **Acute liver failure** reported (rare)

**Timing:** Typically first month of therapy

**Monitoring:**
- **Baseline LFTs**
- **Weekly LFTs** × 4 weeks, then monthly
- Discontinue if ALT >10× ULN or symptomatic hepatitis

## Key Points

### **Therapeutic Drug Monitoring (TDM):**

**Why TDM is Essential:**
1. **Nonlinear pharmacokinetics** (saturated metabolism)
2. **High inter-patient variability** (CYP2C19 polymorphisms)
3. **Narrow therapeutic window** (1-5 µg/mL)
4. **Toxicity risk** if >5 µg/mL
5. **Treatment failure risk** if <1 µg/mL

**Target Trough Levels:**

| Indication | Target Trough | Rationale |
|------------|---------------|-----------|
| **Invasive aspergillosis** | **1-5 µg/mL** | Balance efficacy vs toxicity |
| **CNS infections** | **2-6 µg/mL** | Higher levels needed for CNS penetration |
| **General target** | 1-5 µg/mL | Standard recommendation |

**When to Check Levels:**
- **Steady state** (day 5-7 after starting/dose change)
- Trough level (just before next dose)
- **Weekly initially**, then every 1-2 weeks

### **CYP2C19 Genotype and Dosing:**

**CYP2C19 Polymorphisms:**

| Phenotype | Frequency (Caucasian) | Voriconazole Levels | Dosing Recommendation |
|-----------|----------------------|---------------------|----------------------|
| **Ultrarapid metabolizer (UM)** | 1-5% | **Low** (may fail) | ↑ Dose or alternative agent |
| **Extensive metabolizer (EM)** | 70-80% | Normal | Standard dose |
| **Poor metabolizer (PM)** | 3-5% | **High** (toxicity risk) | ↓ Dose by 50% or alternative |

**Asian populations:** Higher prevalence of PMs (13-23%) → higher toxicity risk

### **Other Notable Side Effects:**

| Side Effect | Frequency | Management |
|-------------|-----------|------------|
| **Rash/photosensitivity** | 5-7% | Sun protection, may require discontinuation |
| **Hallucinations** | Rare | Dose reduction or stop |
| **QTc prolongation** | Rare | Avoid with other QT drugs |
| **Periostitis** (bone pain) | Rare (long-term) | Consider switching to alternative |

### **Drug Interactions (CYP3A4 Inhibitor):**

**Voriconazole INCREASES levels of:**
- **Tacrolimus/cyclosporine** (↓ dose by 50-66%)
- **Sirolimus** (contraindicated)
- **Statins** (rhabdomyolysis risk)
- **Calcium channel blockers**
- **Benzodiazepines** (midazolam, triazolam)
- **Vinca alkaloids** (neurotoxicity)

**Drugs that INCREASE voriconazole:**
- **CYP2C19 inhibitors**: omeprazole, cimetidine (↑ voriconazole levels)

**Drugs that DECREASE voriconazole:**
- **Rifampin, phenytoin, carbamazepine** (contraindicated - induce CYP450)

### **Clinical Pearls:**
- **TDM is MANDATORY** for voriconazole (unlike fluconazole)
- **Visual disturbances** do NOT require discontinuation (benign, reversible)
- **CYP2C19 genotype testing** helpful if available
- **Asian patients** at higher risk for toxicity (more PMs)
- **Hepatotoxicity** more common with pre-existing liver disease (69% vs 16%)
- Avoid **rifampin, phenytoin** (contraindicated - profound interactions)

## Sources

- [Frontiers Pharmacology 2025: Voriconazole Hepatotoxicity Risk Factors]
- [PMC4038142: Voriconazole Metabolism and CYP2C19]
- [PMC11578688: Voriconazole Visual Disturbances and Hallucinations 2024]
- [PMC5474211: CPIC Guideline for CYP2C19 and Voriconazole]

## Media

N/A
